| Product Code: ETC6750093 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Padhi | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Patient Derived Xenograft (PDX) Models Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, 2021 & 2031F |
3.3 China Patient Derived Xenograft (PDX) Models Market - Industry Life Cycle |
3.4 China Patient Derived Xenograft (PDX) Models Market - Porter's Five Forces |
3.5 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Tumor Type, 2021 & 2031F |
3.7 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By Technique, 2021 & 2031F |
3.9 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 China Patient Derived Xenograft (PDX) Models Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for personalized medicine |
4.2.2 Growing focus on precision medicine |
4.2.3 Rising investments in oncology research in China |
4.3 Market Restraints |
4.3.1 Ethical concerns related to the use of animal models |
4.3.2 Regulatory challenges in the development and use of PDX models in China |
5 China Patient Derived Xenograft (PDX) Models Market Trends |
6 China Patient Derived Xenograft (PDX) Models Market, By Types |
6.1 China Patient Derived Xenograft (PDX) Models Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Mice Models, 2021- 2031F |
6.1.4 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Rat Models, 2021- 2031F |
6.2 China Patient Derived Xenograft (PDX) Models Market, By Tumor Type |
6.2.1 Overview and Analysis |
6.2.2 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Gastrointestinal Tumor Models, 2021- 2031F |
6.2.3 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Lung Tumor Models, 2021- 2031F |
6.2.4 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Haematological Tumor Models, 2021- 2031F |
6.3 China Patient Derived Xenograft (PDX) Models Market, By Application |
6.3.1 Overview and Analysis |
6.3.2 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Preclinical Drug Development, 2021- 2031F |
6.3.3 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Precision Medicine, 2021- 2031F |
6.3.4 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Co-Clinical Trials, 2021- 2031F |
6.3.5 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Basic Cancer Research, 2021- 2031F |
6.3.6 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Biomarker Analysis, 2021- 2031F |
6.3.7 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Oncology Research, 2021- 2031F |
6.4 China Patient Derived Xenograft (PDX) Models Market, By Technique |
6.4.1 Overview and Analysis |
6.4.2 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Heterotopic Implantation, 2021- 2031F |
6.4.3 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Orthotropic Implantation, 2021- 2031F |
6.5 China Patient Derived Xenograft (PDX) Models Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Academic and Research Organizations, 2021- 2031F |
6.5.3 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Contract Research Organizations, 2021- 2031F |
6.5.4 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Pharmaceutical and Biotechnological Companies, 2021- 2031F |
6.5.5 China Patient Derived Xenograft (PDX) Models Market Revenues & Volume, By Others, 2021- 2031F |
7 China Patient Derived Xenograft (PDX) Models Market Import-Export Trade Statistics |
7.1 China Patient Derived Xenograft (PDX) Models Market Export to Major Countries |
7.2 China Patient Derived Xenograft (PDX) Models Market Imports from Major Countries |
8 China Patient Derived Xenograft (PDX) Models Market Key Performance Indicators |
8.1 Rate of adoption of PDX models in preclinical research |
8.2 Number of collaborations between research institutions and pharmaceutical companies for PDX model development |
8.3 Success rate of drug discovery and development using PDX models |
9 China Patient Derived Xenograft (PDX) Models Market - Opportunity Assessment |
9.1 China Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 China Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Tumor Type, 2021 & 2031F |
9.3 China Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Application, 2021 & 2031F |
9.4 China Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By Technique, 2021 & 2031F |
9.5 China Patient Derived Xenograft (PDX) Models Market Opportunity Assessment, By End User, 2021 & 2031F |
10 China Patient Derived Xenograft (PDX) Models Market - Competitive Landscape |
10.1 China Patient Derived Xenograft (PDX) Models Market Revenue Share, By Companies, 2024 |
10.2 China Patient Derived Xenograft (PDX) Models Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here